Highlights from the third day included information about Quanterix's new SIMOA One platform, expected to launch at the end of ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and ...

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said on Wednesday that it has closed a $27 million Series E financing round.

The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting.

The UK-based firm has issued five Class II recalls for its RX-series analyzers since 2018 for issues related to reagent carryover between subsequent tests.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.